The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Efficacy observation.
- Who it may be relevant to
- Registry conditions: Squamous Cell Lung Cancer. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Exploration of the Treatment Trajectory and Drug Resistance Mechanism of Immunotherapy Combined With Chemotherapy in Patients With Advanced Lung Squamous Carcinoma
Overview
The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.
Detailed description
The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.
Interventions
- Other Efficacy observation
Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.
Primary outcome measures
- progression-free survival [Time frame: A two-year period after starting treatment (Regular follow-up every three months after receiving immunotherapy combined with or without chemotherapy as first-line treatment)]
Secondary outcome measures (1)
- Overall survival [Time frame: A three-year period after starting treatment (Regular follow-up every six months after receiving immunotherapy combined with or without chemotherapy as first-line treatment)]
Eligibility criteria
Inclusion criteria
- Diagnosed with sq-NSCLC;
- Receiving immunotherapy combined with or without chemotherapy as first-line treatment;
- ≥ 18 years and ≤ 80 years old;
- No previous treatment in the lungs or any other organ.
Exclusion criteria
- History of cancer treatment;
- History of other malignant tumors;
- Irregular treatment or poor compliance;
- Incomplete clinical information or lost to follow-up.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Union Hospital, Tongji Medical college, Huazhong University of Science and Technology — Wuhan
Identifiers
NCT: NCT06647836 · XHJY20240908